http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
체질량지수와 2기, 3기 결직장암 환자의 수술 후 예후와의 관련성
임태완(Tae Wan Lim),유병은(Byung Eun Yoo),신재원(Jae Won Shin),이동원(Dong Won Lee),곽정면(Jung Myun Kwak),김진(Jin Kim),김선한(Seon Hahn Kim) 대한종양외과학회 2013 Korean Journal of Clinical Oncology Vol.9 No.2
Purpose: Obesity increase the risk of colorectal cancer (CRC) but little is known about the influence of obesity on the outcome after surgery in Asaian population. We investigated the effect of body mass index (BMI) on overall survival (OS) and recurrence free survival (RFS) in CRC patients. Methods: This retrospective study included 483 patients with stage II-III CRC who underwent colorectal resection between September 2006 and May 2012 at Korea University Anam Hospital. The authors divided patients into two BMI groups: normal weight group (18.5 to 22.9 kg/㎡) and overweight group (≥23 kg/㎡). Results: In this cohort of patients with stage II-III CRC, 161 patients (33%) were included in the normal weight group and 322 patients (73%) were included in the overweight group. High BMI was associated with better OS (P=0.013) and was an independent prognostic factor for OS in a multivariate analysis (P=0.001). No associations were observed between BMI and RFS. Conclusion: In Korean patients with stage II-III CRC, preoperative overweight was associated with a significant increase in OS, but not RFS. Further studies are needed to determine role of BMI on prognosis in CRC patients.
임상연구 : 항히스타민제 전처치 후 Atracurium Besylate 투여 시 혈역학적 변화의 측정
최영규 ( Young Kyoo Choi ),임태완 ( Tae Wan Lim ),김대언 ( Dae Eon Kim ),이동현 ( Dong Hyun Lee ),박성욱 ( Sung Wook Park ),김건식 ( Keon Sik Kim ),강화자 ( Wha Ja Kang ),이두익 ( Doo Ik Lee ) 대한마취과학회 2007 Korean Journal of Anesthesiology Vol.52 No.6
Background: Hemodynamic changes through the histamine-induced release of atracurium are relatively common, but can be particularly dangerous in hemodynamically unstable patients. This study evaluated the effectiveness of a pretreatment with an anti-histamine agent before the administration of atracurium in the prevention of histamine-induced hemodynamic changes. Methods: Forty-eight ASA class I and II patients were assigned to four groups. Groups 1 and 2 were assigned to receive atracurium through a bolus 0.5 mg/kg. Groups 3 and 4 were assigned to receive atracurium through a bolus 1.0 mg/kg. Group 1 and 3 were pretreated with pheniramine (H1-blocker) and ranitidine (H2-blocker) intravenously before the induction of general anesthesia. After induction, Hemosonic(TM) 100 was installed and the following hemodynamic parameters were measured: systemic vascular resistance (SVR), cardiac index (CI), heart rate (HR) and blood pressure (BP) immediately before, 1, 2, 3, 5 and 10 min after the rapid administration of the atracurium bolus before the skin incision. Results: Groups 1 and 3 showed more stable hemodynamics than groups 2 and 4. Group 2 showed more significant changes in the SVR, CI, BP, HR than group 1 (P<0.05). Group 4 showed more significant changes in the SVR, CI, BP, HR than group 3, and some cases were significant hemodynamically (P<0.05). Group 4 showed more significant changes in the SVR, CI, BP, HR than group 2 (P<0.05). Conclusions: Pretreatment with an anti-histamine drug prior to the administration of atracurium can be effective in attenuating the hemodynamic responses. (Korean J Anesthesiol 2007; 52: 642~8)
Irbesartan과 Lercanidipine의 병용요법이 고혈압 및 혈관재형성에 미치는 효과
이도형, 임태완, 조은지, 박현수, 정상혁, 한주희, 병창선 충남대학교 약학대학 의약품개발연구소 2017 藥學論文集 Vol.32 No.-
Hypertension is one of the major risk factor for cardiovascular disease and can lead to or make worse many complications, heart disease, atherosclerosis and diabetes. Thus, managing blood pressure effec tively using therapeutic drugs such as angiotensin II receptor blocker (ARB) and Ca2+ channel blocker (CCB) can be prevent other complications. Therefore, we investigated the synergistic effect of these two drugs, ir besartan and lercanidipine, for antihypertension, cardioprotection and antidiabetes. Irbesartan (28.74 mg/kg, 14.37 mg/kg) or lercanidipine (1.92 mg/kg, 0.96 mg/kg) alone or combination was administered to sponta-neously hypertensive rats (SHRs) and C57BL/6 mice. A two-week treatment of combination with irbesartan and lercanidipine significantly attenuated systolic blood pressure (SBP) and mean arterial pressure (MAP) compared with monotherapy. Futhermore. the combination therapy protected myocardial ischemia reperfusion injury more effectively than monotherapy. In vascular remodeling, combination therapy significantly diminished cuff -induced neointima formation and reduced serum -indllced vascular smooth muscle cells (VSMCs) pro-liferation compared with monotherapy. However, combination therapy had no significant synergistic effect of blood glucose regulation. Taken together, present study suggest that the combination therapy of irbesartan and lercanidipine may be more effective therapeutic strategy for the treatment of hypertension and related complications, myocardial infarction and arterial restenosis than monotherapy